Multiply antibiotic-resistant Gram-negative bacteria

American Journal of Transplantation

Volumn 4, Issue 10 SUPPL., 2004, Pages 21-24

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN; COTRIMOXAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

BACTERIAL COLONIZATION; BRONCHIOLITIS OBLITERANS; BURKHOLDERIA CEPACIA; CENTRAL VENOUS CATHETER; CYSTIC FIBROSIS; EPIDEMIC; ESCHERICHIA COLI; GASTROINTESTINAL TRACT; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INTENSIVE CARE; INTESTINE TRANSPLANTATION; INTUBATION; KLEBSIELLA; KLEBSIELLA PNEUMONIAE; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; ORGAN TRANSPLANTATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; RISK FACTOR; STENOTROPHOMONAS MALTOPHILIA; ANTIBIOTIC RESISTANCE; MICROBIOLOGY; MULTIDRUG RESISTANCE; POSTOPERATIVE COMPLICATION; TRANSPLANTATION;

DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; POSTOPERATIVE COMPLICATIONS; TRANSPLANTATION;

EID: 16644391969     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6135.2004.00720.x     Document Type: Review

References (28)

1. Green M, Barbadora K. Recovery of ceftazidime-resistant Klebsiella pneumoniae from pediatric liver and intestinal transplant recipients. Pediatr Transplant 1998; 2: 224-30.
2. Paterson DL, Singh N, Rihs JD, Squier C, Rihs BL, Muder RR. Control of an outbreak of infection due to extended-spectrum beta-lactamase-producing Escherichia coli in a liver transplantation unit. Clin Infect Dis 2001; 33: 126-128.
3. Rebuck JA, Olsen KM, Fey PD, Langnas AN, Rupp ME. Characterization of an outbreak due to extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a pediatric intensive care unit transplant population. Clin Infect Dis 2000; 31: 1368-1372.
4. Aris RM, Gilligan PH, Neuringer IP, Gott KK, Rea J, Yankaskas JR. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome. Am J Respir Crit Care Medical 1997; 155: 1699-1704.
5. Kanj SS, Tapson V, Davis RD, Madden J, Browning I. Infections in patients with cystic fibrosis following lung transplantation. Chest 1997; 112: 924-930.
6. Chaparro C, Chamberlain D, Maurer J, Winton T, Dehoyos A, Kesten S. Bronchiolitis obliterans organizing pneumonia (BOOP) in lung transplant recipients. Chest 1996; 110: 1150-1154.
7. Chaparro C, Maurer J, Gutierrez C et al. Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Medical 2001; 163: 43-48.
8. De Soyza A, McDowell A, Archer L et al. Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis. Lancet 2001; 358: 1780-1781.
9. Aris RM, Routh JC, LiPuma JJ, Heath DG, Gilligan PH. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type. Am J Respir Crit Care Medical 2001; 164: 2102-2106.
10. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32: 1162-1171.
11. Pena C, Pujol M, Ardanuy C et al. An outbreak of hospital-acquired Klebsiella pneumoniae bacteraemia, including strains producing extended-spectrum beta-lactamase. J Hosp Infect 2001; 47: 53-59.
12. Lucet JC, Chevret S, Decre D et al. Outbreak of multiply resistant enterobacteriaceae in an intensive care unit: epidemiology and risk factors for acquisition. Clin Infect Dis 1996; 22: 430-436.
13. Schiappa DA, Hayden MK, Matushek MG et al. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. J Infect Dis 1996; 174: 529-536.
14. Troillet N, Samore MH, Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis 1997; 25: 1094-1098.
15. Snell GI, de Hoyos A, Krajden M, Winton T, Maurer JR. Pseudomonas cepacia in lung transplant recipients with cystic fibrosis. Chest 1993; 103: 466-471.
16. Steinbach S, Sun L, Jiang RZ et al. Transmissibility of Pseudomonas cepacia infection in clinic patients and lung-transplant recipients with cystic fibrosis. N Engl J Medical 1994; 331: 981-987.
17. Ebner W, Kropec-Hubner A, Daschner FD. Bacterial resistance and overgrowth due to selective decontamination of the digestive tract. Eur J Clin Microbiol Infect Dis 2000; 19: 243-247.
18. NCCLS. Performance standards for antimicrobial susceptibility testing. Wayne, PA: NCCLS, 2000.
19. Burns JL, Saiman L, Whittier S et al. Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. Diagn Microbiol Infect Dis 2001; 39: 257-260.
20. Paterson DL, Yu VL. Extended-spectrum beta-lactamases: a call for improved detection and control. Clin Infect Dis 1999; 29: 1419-1422.
21. Lucet JC, Decre D, Fichelle A et al. Control of a prolonged outbreak of extended-spectrum beta-lactamase-producing enterobacteriaceae in a university hospital. Clin Infect Dis 1999; 29: 1411-1418.
22. Rahal JJ. Urban C, Horn D et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998; 280: 1233-1237.
23. Govan JR, Brown PH, Maddison J et al. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet 1993; 342: 15-19.
24. McCallum SJ, Corkill J, Gallagher M, Ledson MJ, Hart CA, Walshaw MJ. Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonised by P aeruginosa. Lancet 2001; 358: 558-560.
25. Szabo D, Mathe A, Filetoth Z. Anderlik P, Rokusz L, Rozgonyi F. In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain. Antimicrob Agents Chemother 2001; 45: 1287-1291.
26. Saiman L, Mehar F, Niu WW et al. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis 1996; 23: 532-537.
27. Beringer P. The clinical use of colistin in patients with cystic fibrosis. Curr Opin Pulm Medical 2001; 7: 434-440.
28. Bonacorsi S, Fitoussi F, Lhopital S, Bingen E. Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 1999; 43: 213-217.